Banner

COVID-19 – Saudi Arabia approved AstraZeneca, Moderna vaccines

Illustration. The Saudi Ministry of Health has approved two additional COVID-19 vaccines, developed by AstraZeneca and Moderna, for use in the kingdom. (torstensimon from Pixabay)

Jakarta (Indonesia Window) – The Saudi Ministry of Health has approved two additional COVID-19 vaccines, developed by AstraZeneca and Moderna, for use in the kingdom.

Earlier, the Pfizer/BioNTech vaccine is already being used to immunize people in the country.

Ibrahim Al-Oraifi, director general of health affairs in the Eastern Province, told Al Arabiya news channel that there is global competition for available supplies of vaccines, and that the demand for the Pfizer vaccine is “great.”

However, he added that Saudi authorities have secured good quantities and vaccination efforts are being stepped up.

“There is an increase in the number of workers in vaccine centers in the kingdom as they gain good experience, where the workflow became faster and larger with the expansion of the reception halls for the vaccine recipients,” he added.

According to Al-Oraifi, a vaccination center in Al-Ahsa is ready to open, and just waiting for the delivery of vaccines.

“We will start within a week or two. Meanwhile, work is underway to equip the Hafar Al-Batin center, which is expected to start operating next month,” he said.

He noted that about 400,000 people in the Eastern Province have registered through the ministry’s Sehaty health services app to receive vaccinations, and about 60,000 people have already been inoculated.

Nationwide, more than 2 million people registered for the vaccine in the first month after the registration process was launched.

According to statistics for the past month, the Ministry of Health is currently receiving 100,000 doses of the Pfizer/BioNTech vaccine a week to reach at least 80 percent immunity among the population through vaccination.

Reporting by Indonesia Window

Tinggalkan Komentar

Your email address will not be published. Required fields are marked *

Iklan